RNS Number : 7759Y Stifel Nicolaus Europe Limited 01 August 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 3617Y Stifel Nicolaus Europe Limited 30 July 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name of
RNS Number : 2520Y Renalytix PLC 30 July 2024 Renalytix plc ("Renalytix" or the "Company") Total Voting Rights LONDON and NEW YORK , 30 July 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at today's date, the Company's total issued share capital is 165,925,513
RNS Number : 5706W Stifel Nicolaus Europe Limited 16 July 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name of
RNS Number : 3963W Stifel Nicolaus Europe Limited 15 July 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name of
RNS Number : 3140W Renalytix PLC 15 July 2024 Renalytix plc ("Renalytix" or the "Company") Issue of Shares and Rule 2.9 Announcement LONDON and NEW YORK - July 15, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the principal amount of the
RNS Number : 2142W Stifel Nicolaus Europe Limited 12 July 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name of
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a
RNS Number : 0325W Stifel Nicolaus Europe Limited 11 July 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name of
RNS Number : 9992V Renalytix PLC 11 July 2024 Renalytix plc ("Renalytix" or the "Company") Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US LONDON and NEW YORK , July 11, 2024 - Renalytix plc (NASDAQ:
